Prosecution Insights
Last updated: April 19, 2026
Application No. 18/050,371

QUANTUM DOT-CONTAINING POLYMERIZABLE COMPOSITION, CURED PRODUCT, WAVELENGTH CONVERSION MEMBER, BACKLIGHT UNIT, AND LIQUID CRYSTAL DISPLAY DEVICE

Final Rejection §102§112
Filed
Oct 27, 2022
Examiner
CAI, WENWEN
Art Unit
1763
Tech Center
1700 — Chemical & Materials Engineering
Assignee
Fujifilm Corporation
OA Round
2 (Final)
60%
Grant Probability
Moderate
3-4
OA Rounds
3y 2m
To Grant
80%
With Interview

Examiner Intelligence

Grants 60% of resolved cases
60%
Career Allow Rate
509 granted / 850 resolved
-5.1% vs TC avg
Strong +20% interview lift
Without
With
+19.8%
Interview Lift
resolved cases with interview
Typical timeline
3y 2m
Avg Prosecution
74 currently pending
Career history
924
Total Applications
across all art units

Statute-Specific Performance

§101
0.8%
-39.2% vs TC avg
§103
43.6%
+3.6% vs TC avg
§102
17.4%
-22.6% vs TC avg
§112
27.9%
-12.1% vs TC avg
Black line = Tech Center average estimate • Based on career data from 850 resolved cases

Office Action

§102 §112
DETAILED ACTION The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Response to Amendment The amendment of claim 1 is supported by the specification. The new claim 17 is supported by the specification. Any rejections and/or objections made in the previous Office action and not repeated below are hereby withdrawn. The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action. The new grounds of rejection set forth below are necessitated by applicant's amendment filed on 12/9/2025. Thus, the following action is properly made final. Claim Rejections - 35 USC § 112 Claims 1-13, 17 rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor, or for pre-AIA the applicant regards as the invention. Claim 1 recites “a monofunctional or polyfunctional (meth)acrylate having a functional group selected from the group consisting of…”. The language is not clear. For purposes of expediting prosecution, the claim is interpreted as “having a functional group…” only applies to polyfunctional (meth)acrylate. Claim Rejections - 35 USC § 102 Claim(s) 1-13, 17 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Yahata et al (WO2019189495). In setting forth this rejection an equivalent document, US 2021/0040383, of WO2019189495 has been relied upon and all citations to paragraph numbers in the discussion below are with respect to the USPGPub. Claims 1-2, 4-6, 8-11, 13: Yahata teaches a cured product prepared from a curable polymerizable composition comprising a quantum dot, 19.37 wt% of a polyfunctional thiol pentaerythritol tetrakis(3-mercaptopropionate) (Mw 488), tricyclodecane dimethanol diacrylate, isobornyl acrylate (Mw 208) [0228-0234]. Claim 3, 7, 12: the polyfunctional thiol can be bis-, tri-, tetrakis-, hexakis-functional thiol [0169]. The trifunctional thiol trimethylolpropane tris(3-mercaptopropionate) has a Mw of 398. Claims 1-2, 4-6, 8-11, 13, 17: Yahata teaches a cured product prepared from a curable polymerizable composition comprising a quantum dot, 18.04 wt% of a polyfunctional thiol pentaerythritol tetrakis(3-mercaptopropionate) (Mw 488), tricyclodecane dimethanol diacrylate, and 7.7wt% of isobornyl acrylate (Mw 208) (8.55*0.9=7.7) [example 9]. Response to Arguments Applicant's arguments filed 12/9/2025 have been fully considered but they are not persuasive. In response to applicant's argument that isobornyl acrylate is not the second (meth)acrylate specified in claim 1, it is noted that claim interpretations for the 112(b) rejection above is based on the following factors: 1) multiple dependent claims recites “the second (meth)acrylate is a monofunctional (meth)acrylate”; 2) PGPub of instant specification [0067] discloses: “the second (meth)acrylate…preferably a monofunctional (meth)acrylate. The monofunctional (meth)acrylate can be represented by the formula A-L-X.” It is not a definition of the monofunctional (meth)acrylate, instead it merely exemplifies the monofunctional (meth)acrylate. 3) PGPub [0079] discloses: such a monofunctional (meth)acrylate does not include the monofunctional (meth)acrylate having the above mentioned functional group. The language distinguishes monofunctional (meth)acrylate from monofunctional (meth)acrylate having the above mentioned functional group. In view of all the factors above and the fact that it is improper to import claim limitations from the specification, it is reasonable to question the scope of the monofunctional (meth)acrylate recited in claim 1. Conclusion Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to WENWEN CAI whose telephone number is (571)270-3590. The examiner can normally be reached on M-F 9am-6pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Joseph Del Sole can be reached on (571)272-1130. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /WENWEN CAI/ Primary Examiner, Art Unit 1763
Read full office action

Prosecution Timeline

Oct 27, 2022
Application Filed
Sep 08, 2025
Non-Final Rejection — §102, §112
Dec 09, 2025
Response Filed
Jan 14, 2026
Final Rejection — §102, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12600886
RESINS FOR ADHESIVE BONDING OF FABRICS
2y 5m to grant Granted Apr 14, 2026
Patent 12590201
DEGRADATION PROMOTER FOR ALIPHATIC POLYESTER BIODEGRADABLE RESIN, BIODEGRADABLE RESIN COMPOSITION, AND METHOD FOR PROMOTING DEGRADATION OF ALIPHATIC POLYESTER BIODEGRADABLE RESIN
2y 5m to grant Granted Mar 31, 2026
Patent 12559592
BRANCHED AMORPHOUS POLYAMIDE (CO)POLYMERS AND METHODS OF MAKING AND USING SAME
2y 5m to grant Granted Feb 24, 2026
Patent 12552956
PHOTOPOLYMERIZABLE TYPE DENTAL SURFACE COATING COMPOSITION
2y 5m to grant Granted Feb 17, 2026
Patent 12534556
CURABLE COMPOSITION, CURED ARTICLE USING SAME, AND METHOD FOR PRODUCING CURED ARTICLE
2y 5m to grant Granted Jan 27, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

3-4
Expected OA Rounds
60%
Grant Probability
80%
With Interview (+19.8%)
3y 2m
Median Time to Grant
Moderate
PTA Risk
Based on 850 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month